- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCTIC BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 13.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Notice of Annual General Meeting on 27 May 2026 | 2 | Cision News | ||
| 08.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience presents HeROPA data at EADV in Athens | 1 | Cision News | ||
| 07.05. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Annual report 2025 | 1 | Cision News | ||
| 30.04. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - 78% growth in Nutra revenues | 1 | Cision News | ||
| 24.04. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Invitation to presentation of Q1 2026 operational update | 2 | Cision News | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - New long-term financing | 1 | Oslo Børs | ||
| 01.04. | Arctic Bioscience AS: Arctic Bioscience - Primary insiders who have provided bank guarantee | - | Oslo Børs | ||
| 19.03. | Arctic Bioscience AS: Arctic Bioscience - New peer-reviewed study shows herring roe phospholipids stimulate anti-inflammatory pathways in cells | - | Oslo Børs | ||
| 26.02. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q4 2025 Operational update - Positive outlook for 2026 | 3 | Cision News | ||
| 23.02. | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of Q4 2025 operational update | 2 | Oslo Børs | ||
| 29.01. | ARCTIC BIOSCIENCE AS: Arctic Bioscience invited to present at the Glaucoma 360 New Horizons Forum | 3 | Cision News | ||
| 18.12.25 | Arctic Bioscience AS: Financial calendar | - | Oslo Børs | ||
| 17.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Share capital increase registered | 2 | Cision News | ||
| 12.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Board approval of share capital increase related to conversion of debt | 1 | Cision News | ||
| 09.12.25 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Exercise of right to convert debt and issuance of shares | 1 | Cision News |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RELAY THERAPEUTICS | 12,070 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| NUVALENT | 101,00 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,27 | 0,00 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| ERASCA | 10,320 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,330 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| QIAGEN | 29,715 | +3,90 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,920 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | - Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 - - Positive cardiopulmonary results and long-term... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,300 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 19,500 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 2,850 | 0,00 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| PRAXIS PRECISION MEDICINES | 321,05 | +0,14 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 26,030 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026) | ||
| COGENT BIOSCIENCES | 31,260 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| ABSCI | 4,630 | 0,00 % | Speicher und Bürgerenergie prägen ABSI-Jahrestagung in Neuötting | Auf der 33. Jahrestagung der Arbeitsgemeinschaft Bayerischer Solarinitiativen (ABSI) diskutierten rund 240 Fachleute über die zukünftige Rolle von Stromspeichern und Bürgerenergie. Im Zentrum stand... ► Artikel lesen | |
| TYRA BIOSCIENCES | 33,750 | -0,09 % | Wolfe Research initiates Tyra Biosciences stock at Peerperform |
ARCTIC BIOSCIENCE AS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCTIC BIOSCIENCE AS finden Sie auf Wallstreet Online.